Literature DB >> 16437549

Proposed structural models of the prothrombinase (FXa-FVa) complex.

Ludovic Autin1, Mårten Steen, Björn Dahlbäck, Bruno O Villoutreix.   

Abstract

Activated coagulation factor V (FVa) functions as a cofactor to factor Xa (FXa) in the conversion of prothrombin (PT) to thrombin. This essential procoagulant reaction, despite being the subject of extensive investigation, is not fully understood structurally and functionally. To elucidate the structure of the FXa-FVa complex, we have performed protein:protein (Pr:Pr) docking simulation with the pseudo-Brownian Pr:Pr docking ICM package and with the shape-complementarity Pr:Pr docking program PPD. The docking runs were carried out using a new model of full-length human FVa and the X-ray structure of human FXa. Five representative models of the FXa-FVa complex were in overall agreement with some of the available experimental data, but only one model was found to be consistent with almost all of the reported experimental results. The use of hybrid docking approach (theoretical plus experimental) is definitively important to study such large macromolecular complexes. The FXa-FVa model we have created will be instrumental for further investigation of this macromolecular system and will guide future site directed mutagenesis experiments. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16437549     DOI: 10.1002/prot.20848

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  16 in total

1.  Membrane-dependent interaction of factor Xa and prothrombin with factor Va in the prothrombinase complex.

Authors:  Shabir H Qureshi; Likui Yang; Chandrashekhara Manithody; Alireza R Rezaie
Journal:  Biochemistry       Date:  2009-06-09       Impact factor: 3.162

Review 2.  Nanoscale studies of protein-membrane interactions in blood clotting.

Authors:  J H Morrissey; E Tajkhorshid; C M Rienstra
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

3.  An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase.

Authors:  Sai K Buddai; Juliana M Layzer; Genmin Lu; Christopher P Rusconi; Bruce A Sullenger; Dougald M Monroe; Sriram Krishnaswamy
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

4.  Location of the multimerin 1 binding site in coagulation factor V: an update.

Authors:  Samira B Jeimy; Mary Ann Quinn-Allen; Nola Fuller; William H Kane; Catherine P M Hayward
Journal:  Thromb Res       Date:  2008-05-02       Impact factor: 3.944

Review 5.  Novel blood coagulation molecules: Skeletal muscle myosin and cardiac myosin.

Authors:  Hiroshi Deguchi; Shravan Morla; John H Griffin
Journal:  J Thromb Haemost       Date:  2020-10-25       Impact factor: 5.824

6.  Mapping of the factor Xa binding site on factor Va by site-directed mutagenesis.

Authors:  Mårten Steen; Sinh Tran; Ludovic Autin; Bruno O Villoutreix; Ann-Louise Tholander; Björn Dahlbäck
Journal:  J Biol Chem       Date:  2008-05-23       Impact factor: 5.157

7.  FRET studies with factor X mutants provide insight into the topography of the membrane-bound factor X/Xa.

Authors:  Shabir H Qureshi; Likui Yang; Subramanian Yegneswaran; Alireza R Rezaie
Journal:  Biochem J       Date:  2007-11-01       Impact factor: 3.857

Review 8.  Exosites in the substrate specificity of blood coagulation reactions.

Authors:  P E Bock; P Panizzi; I M A Verhamme
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

9.  Modeling of human factor Va inactivation by activated protein C.

Authors:  Maria Cristina Bravo; Thomas Orfeo; Kenneth G Mann; Stephen J Everse
Journal:  BMC Syst Biol       Date:  2012-05-20

10.  Screening Outside the Catalytic Site: Inhibition of Macromolecular Inter-actions Through Structure-Based Virtual Ligand Screening Experiments.

Authors:  Olivier Sperandio; Maria A Miteva; Kenneth Segers; Gerry A F Nicolaes; Bruno O Villoutreix
Journal:  Open Biochem J       Date:  2008-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.